A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate

Minimum of 1 mg/day oral (or folinic acid 5 mg/week)

15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)

100 mg intravenous (IV) prior to each rituximab infusion (For Arm B, for the Months 6 and 18 cycles, IV saline was administered prior to each placebo infusion)

To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.

500 mg or 1000 mg IV\*2.